Targeting Therapeutic Resistance in Colorectal Cancer
Abstract
Colorectal cancer is a leading cause of cancer-related deaths in the United States. The Department of Veterans Affairs recognizes colorectal cancer as a disease caused by exposure to ionizing radiation during service. Colorectal cancer is one of the major causes of morbidity and mortality among Veterans. While early stages of colorectal cancer are highly curable by surgical resection, the prognosis of patients with metastatic disease remains grave. Promising targeted colorectal cancer therapies, including monoclonal antibodies against Epidermal Growth Factor Receptor, have resulted in significant improvement of overall survival in patients with metastatic disease; however, the success is limited by the emergence of cancer resistance. The proposed studies aim to develop novel anti-cancer agents to overcome therapeutic resistance in patients with metastatic colorectal cancer. These experimental approaches will pave the way towards further Investigational New Drug-enabling studies and inform the design of future clinical trials in patients. Identification and selective targeting of tumor cells, which are resistant to currently available therapies, will ultimately lead to successful abrogation of clinical disease and improve quality of life and survival of Veterans suffering from colorectal cancer.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Aug 07, 2017
- Source ID
- W81XWH1710218
Entities
People
- Christine Lian
Organizations
- United States Army